UPDATE: Canaccord Genuity Starts Synageva BioPharma (GEVA) at Buy; Attractive Orphan Platform
Tweet
Share
E-mailGet Alerts GEVA Hot Sheet
Price: $238.60 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
(Updated - June 25, 2012 8:20 AM EDT)
Canaccord Genuity initiates coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy. PT $60.00.
Analyst, Salveen Richter, said, "The key value driver is SBC-102, an enzyme replacement therapy for lysosomal acid lipase deficiency (LAL-D), a rare, severe, unmet disorder, with positive Phase 1/2 proof-of-concept data and a pivotal trial to initiate in late 2012/early 2013. The company’s novel protein expression platform has produced four additional pipeline drugs (including a protein therapy), the lead being SBC-103, a pre-clinical therapeutic for MPS IIIB, which represent potential upside."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $38.50 yesterday.
Canaccord Genuity initiates coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy. PT $60.00.
Analyst, Salveen Richter, said, "The key value driver is SBC-102, an enzyme replacement therapy for lysosomal acid lipase deficiency (LAL-D), a rare, severe, unmet disorder, with positive Phase 1/2 proof-of-concept data and a pivotal trial to initiate in late 2012/early 2013. The company’s novel protein expression platform has produced four additional pipeline drugs (including a protein therapy), the lead being SBC-103, a pre-clinical therapeutic for MPS IIIB, which represent potential upside."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $38.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Urban Company (URBANCO:IN) at Buy
- BMO Capital Starts AMD (AMD) at Outperform
- BMO Capital Starts NVIDIA (NVDA) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
